Halozyme Therapeutics HALO Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's operating lease right-of-use assets in other assets?
- Halozyme Therapeutics (HALO) reported operating lease right-of-use assets in other assets of $35.3M in Q1 2026.
- How has Halozyme Therapeutics's operating lease right-of-use assets in other assets changed year-over-year?
- Halozyme Therapeutics's operating lease right-of-use assets in other assets increased by 8.3% year-over-year, from $32.59M to $35.3M.
- What is the long-term trend for Halozyme Therapeutics's operating lease right-of-use assets in other assets?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's operating lease right-of-use assets in other assets has grown at a 62.8% compound annual growth rate (CAGR), from $3.3M to $37.7M.